Eloxatin
Complete Remission Rate, CRR
Sun Yat-sen UniversityN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Complete Remission Rate, CRR cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tucidinostat Sun Yat-sen University | N/A | D |
Azacitidine Sun Yat-sen University | N/A | D |
Same molecule, other indications
Eloxatin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →